Fiebig H H, Schuchhardt C, Henss H, Fiedler L, Löhr G W
Behring Inst Mitt. 1984 May(74):343-52.
In 34 tumors of different origin 50 comparisons between the tumor response in the patients and in nude mice were performed. Combination chemotherapy was more successful than single agent chemotherapy. Out of the 25 combinations given, 9 (36%) effected a remission in comparison to 4 out of 25 (16%) after single agent chemotherapy. 13 patients got a remission which was found in 12 cases in the nude mouse, too. 37 patients did not respond to treatment and the same result was found in 36 cases in the nude mouse system. Xenografts gave a correct prediction for resistance in 97% and for tumor response in 92%. Despite great efforts to obtain a large number of comparisons, only 22 test results were available before the patients needed chemotherapy. In 13 cases chemotherapy was done simultaneously in the patient and in the nude mouse system. In 15 cases the patients were treated first. The xenograft system will not have practical significance in determining the treatment of the patients. Limitations are the duration of the testing, the testing rate of about 50% and the charges for nude mice. However, the highly correct prediction rates for tumor sensitivity and resistance validates human tumor xenografts as tumor models to test new drugs and combinations.
在34例不同来源的肿瘤中，对患者和裸鼠的肿瘤反应进行了50次比较。联合化疗比单药化疗更成功。在给出的25种联合化疗方案中，有9种（36%）实现了缓解，而单药化疗的25种方案中只有4种（16%）实现缓解。13例患者获得缓解，在裸鼠中也有12例出现同样情况。37例患者对治疗无反应，在裸鼠系统中36例也是同样结果。异种移植对耐药性的预测准确率为97%，对肿瘤反应的预测准确率为92%。尽管为获得大量比较结果付出了巨大努力，但在患者需要化疗之前，仅得到了22个测试结果。13例患者同时在患者和裸鼠系统中进行化疗。15例患者先接受治疗。异种移植系统在确定患者治疗方案方面没有实际意义。局限性在于测试持续时间、约50%的测试率以及裸鼠费用。然而，对肿瘤敏感性和耐药性的高度准确预测率证实了人肿瘤异种移植作为测试新药和联合用药的肿瘤模型的有效性。
